Gilead Sciences (CHIX:GISD) Other Long-Term Liabilities : €1,239 Mil (As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Gilead Sciences Other Long-Term Liabilities?

Gilead Sciences's other long-term liabilities for the quarter that ended in Mar. 2025 was €1,239 Mil.

Gilead Sciences's quarterly other long-term liabilities declined from Sep. 2024 (€1,260 Mil) to Dec. 2024 (€1,237 Mil) but then increased from Dec. 2024 (€1,237 Mil) to Mar. 2025 (€1,239 Mil).

Gilead Sciences's annual other long-term liabilities increased from Dec. 2022 (€1,112 Mil) to Dec. 2023 (€1,174 Mil) and increased from Dec. 2023 (€1,174 Mil) to Dec. 2024 (€1,237 Mil).

Gilead Sciences Other Long-Term Liabilities Historical Data

The historical data trend for Gilead Sciences's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Other Long-Term Liabilities Chart

Gilead Sciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

Get a 7-Day Free Trial

997.91

863.76

1,112.03

1,173.76

1,236.73

Gilead Sciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Other Long-Term Liabilities	Get a 7-Day Free Trial															1,282.48	1,316.39	1,259.60	1,236.73	1,238.58

Gilead Sciences Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Gilead Sciences Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (CHIX:GISd) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico 1GILD:Italy 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD:Canada GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster City, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Headlines

No Headlines